TrialModern rheumatology2009

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.

Norihiro Nishimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.